We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $27.71 · 7 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Director at Kestra Medical (KMTS) sells 15,000 common shares - Stock Titan
Director at Kestra Medical (KMTS) sells 15,000 common shares Stock Titan
[144] KESTRA MEDICAL TECHNOLOGIES, LTD. SEC Filing - Stock Titan
[144] KESTRA MEDICAL TECHNOLOGIES, LTD. SEC Filing Stock Titan
Kestra Medical Technologies to Present at the BofA Securities 2026 Healthcare Conference
Kestra Medical Technologies to Present at the BofA Securities 2026 Healthcare Conference - Yahoo Finance
Kestra Medical Technologies to Present at the BofA Securities 2026 Healthcare Conference Yahoo Finance
Kestra Showcases Accelerated Innovation at HRS 2026
Kestra Medical Technologies Insider Sold Shares Worth $300,671, According to a Recent SEC Filing
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 03. 17. | After market close (AMC) | $-0.58 | — | — | $26.48M | — | Scheduled |
| FY2026 Q3 | 2025. 01. 31. | Time TBD | — | $-3.56 | — | — | $42.58M | Reported |
| FY2025 Q2 | 2024. 10. 31. | Time TBD | — | $-2.31 | — | — | $27.49M | Reported |
| FY2025 Q1 | 2024. 07. 31. | Time TBD | — | $-1.12 | — | — | $12.78M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 04. 10. | Goldman Sachs | — | Maintain | Neutral → Neutral | — | Goldman Sachs: Neutral |
| 2026. 04. 07. | BTIG | — | Maintain | Buy → Buy | — | BTIG: Buy |
Compare a firm's past rating changes and its actions on other stocks in the same sector.
Price data
Filings, earnings, and institutional changes summarized in one paragraph, with source links.
No holdings data to show.
See new positions, full exits, and weight changes.